{"schema_version":"secwatch.filing_event.v1","accession":"0001174947-23-000915","form_type":"8-K","ticker":"CNMD","cik":"0000816956","company_name":"CONMED Corp","filed_at":"2023-07-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.720263+00:00","generated_at":"2026-06-13T02:34:46.554563+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CONMED Q2 sales +14.6% to $317.7M, adj. EPS $0.83, raises FY guidance","bullets":["GAAP diluted EPS $0.43 vs loss of $5.65; adjusted diluted EPS $0.83, +9.2% YoY.","Revenue $317.7M (+14.6% as reported, +16.6% constant currency); acquisitions added ~400 bps.","Domestic sales +17.1%; International sales +11.7% as reported (+16.0% constant currency).","Orthopedic Surgery +17.1%, General Surgery +12.6% as reported.","FY 2023 revenue guidance raised to $1.230-1.260B; adjusted EPS guidance raised to $3.40-3.55."],"urls":{"canonical":"https://secwatch.observer/filing/0001174947-23-000915","json":"https://secwatch.observer/filing/0001174947-23-000915.json","markdown":"https://secwatch.observer/filing/0001174947-23-000915.md","text":"https://secwatch.observer/filing/0001174947-23-000915.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/816956/000117494723000915/0001174947-23-000915-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/816956/000117494723000915/form8k-30543_cnmd.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T02:34:46.554563+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f89158b598a8051a2913183f9d792e8c1cf2c7cb","claim":"CONMED Corp reported second quarter ended June 30, 2023 results: revenue $317.7 million, net income $13,732, EPS $0.43. Guidance raised.","evidence_excerpt":"Florida, July 26, 2023 – CONMED Corporation (NYSE: CNMD) today announced financial results for the second quarter ended June 30, 2023. Second Quarter 2023 Highlights · Sales of $317.7 million increased 14.6% year over year as reported and 16.6% in constant currency. Acquisitions contributed approximately 400 basis points of growth. · Domestic revenue increased 17.1%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/816956/000117494723000915/0001174947-23-000915-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Revenue","value":"$317.7 million"},{"label":"Net income","value":"$13,732"},{"label":"EPS","value":"$0.43"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}